Verrecchia F - Search Results

1

Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes.

Vija L, Farge D, Gautier JF, Vexiau P, Dumitrache C, Bourgarit A, Verrecchia F, Larghero J. Vija L, et al. Among authors: verrecchia f. Diabetes Metab. 2009 Apr;35(2):85-93. doi: 10.1016/j.diabet.2008.10.003. Epub 2009 Feb 20. Diabetes Metab. 2009. PMID: 19230736 Review.

2

[Involvement of TGFbeta1 in fibrotic diseases: role of its effectors, the Smad proteins].

Dennler S, Laboureau J, Farge D, Mauviel A, Verrecchia F. Dennler S, et al. Among authors: verrecchia f. Rev Med Interne. 2006 Jan;27(1):46-9. doi: 10.1016/j.revmed.2005.10.004. Epub 2005 Nov 22. Rev Med Interne. 2006. PMID: 16330131 French.

3

Modulation of collagen and MMP-1 gene expression in fibroblasts by the immunosuppressive drug rapamycin. A direct role as an antifibrotic agent?

Poulalhon N, Farge D, Roos N, Tacheau C, Neuzillet C, Michel L, Mauviel A, Verrecchia F. Poulalhon N, et al. Among authors: verrecchia f. J Biol Chem. 2006 Nov 3;281(44):33045-52. doi: 10.1074/jbc.M606366200. Epub 2006 Aug 16. J Biol Chem. 2006. PMID: 16914544 Free article.

4

Transforming growth factor-beta signaling through the Smad proteins: role in systemic sclerosis.

Verrecchia F, Mauviel A, Farge D. Verrecchia F, et al. Autoimmun Rev. 2006 Oct;5(8):563-9. doi: 10.1016/j.autrev.2006.06.001. Epub 2006 Jul 5. Autoimmun Rev. 2006. PMID: 17027893 Review.

5

Skin involvement in scleroderma--where histological and clinical scores meet.

Verrecchia F, Laboureau J, Verola O, Roos N, Porcher R, Bruneval P, Ertault M, Tiev K, Michel L, Mauviel A, Farge D. Verrecchia F, et al. Rheumatology (Oxford). 2007 May;46(5):833-41. doi: 10.1093/rheumatology/kel451. Epub 2007 Jan 25. Rheumatology (Oxford). 2007. PMID: 17255134

6

In vitro evidence for a direct antifibrotic role of the immunosuppressive drug mycophenolate mofetil.

Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, Verrecchia F. Roos N, et al. Among authors: verrecchia f. J Pharmacol Exp Ther. 2007 May;321(2):583-9. doi: 10.1124/jpet.106.117051. Epub 2007 Feb 1. J Pharmacol Exp Ther. 2007. PMID: 17272676

7

Phenotypical and functional characteristics of in vitro expanded bone marrow mesenchymal stem cells from patients with systemic sclerosis.

Larghero J, Farge D, Braccini A, Lecourt S, Scherberich A, Foïs E, Verrecchia F, Daikeler T, Gluckman E, Tyndall A, Bocelli-Tyndall C. Larghero J, et al. Among authors: verrecchia f. Ann Rheum Dis. 2008 Apr;67(4):443-9. doi: 10.1136/ard.2007.071233. Epub 2007 May 25. Ann Rheum Dis. 2008. PMID: 17526552

8

Involvement of ERK signaling in halofuginone-driven inhibition of fibroblast ability to contract collagen lattices.

Tacheau C, Michel L, Farge D, Mauviel A, Verrecchia F. Tacheau C, et al. Among authors: verrecchia f. Eur J Pharmacol. 2007 Nov 14;573(1-3):65-9. doi: 10.1016/j.ejphar.2007.07.030. Epub 2007 Jul 24. Eur J Pharmacol. 2007. PMID: 17706637

9

[Mesenchymal stem cells and immunomodulation: toward new immunosuppressive strategies for the treatment of autoimmune diseases?].

Larghero J, Vija L, Lecourt S, Michel L, Verrecchia F, Farge D. Larghero J, et al. Among authors: verrecchia f. Rev Med Interne. 2009 Mar;30(3):287-99. doi: 10.1016/j.revmed.2008.08.019. Epub 2008 Oct 17. Rev Med Interne. 2009. PMID: 18930338 Review. French.

10

[Do specific antifibrotic properties of immunosuppressive drugs used in the treatment of systemic sclerosis exist?].

Verrecchia F, Michel L, Keshtmand H, Wang Y, Launay D, Farge D. Verrecchia F, et al. Rev Med Interne. 2009 Nov;30(11):955-62. doi: 10.1016/j.revmed.2009.02.019. Epub 2009 Apr 5. Rev Med Interne. 2009. PMID: 19349102 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

124 results

Search Page